As benefits seem to outweigh risks for patients with t(11;14), the amyloidosis community is eagerly awaiting the FDA to lift the hold so that venetoclax can be tested in clinical trials in patients with t(11;14) AL amyloidosis. The BCMA-targeting antibody-drug conjugate belantamab mafodoti...
In recent years, the development of new drugs has brought new hope to patients. This review presents the latest advances in drug development and clinical application to provide a reference for clinicians managing transthyretin cardiac amyloidosis....
2023) with one exception. Unlike in previous years, we have included cellular and gene therapies approved by the FDA (U.S. Food and Drug Administration2023a,b) into our analysis. However, we exclude generics, or generic versions of
Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of multiple myeloma and light chain (AL) amyloidosis. Darzalex Faspro (daratumumab and hyaluronidase-fihj)-Based Qu...
Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s Non-insulin-dependent diabetes mellitus (NIDDM, type 2 diabetes) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin... Professor,André,J.,... - 《Drugs》 被引量: 475发表: 1997年 Drug...
The Aβ hypothesis is the mainstream hypothesis for the pathogenesis of AD and has influenced the direction of drug development over the past three decades. According to the hypothesis, the pathological progression of AD originates from asymptomatic cerebral amyloidosis many years before the onset of...
Ixazomib is a novel oral proteasome inhibitor which is being studied in multiple myeloma and systemic light-chain (AL) amyloidosis, and other malignancies. Ixazomib was granted orphan drug designation for the treatment of patients with relapsed or refractory multiple myeloma by the Ministry of Health...
Immunomodulatory drugs (IMiDs) have become an integral part of therapy for both newly diagnosed and relapsed/refractory multiple myeloma (RRMM). IMiDs bind
Amvuttra (Vutrisiran) Subcutaneous Injection 25 mg/0.5 mL is given once every three months to treat polyneuropathy caused by an illness called hereditary ATTR amyloidosis in adults. The drug comes with a warning of reduced serum vitamin A levels. Vutrisiran is a chemically modi...
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. (IR)-mediated signal transduction in the brain, as suggested by decreased IR beta-subunit (IRbeta) Y1162/1163 autophosphorylation and reduced ... L Ho,W Qin,PN Pompl,... - 《Faseb ...